

WBC	5.0			x10E3/u L	3.4-10.8	01	F
RBC	5.22			x10E6/u L	4.14-5.80	01	F
Hemoglobin	15.7			g/dL	13.0-17.7	01	F
Hematocrit	46.2			%	37.5-51.0	01	F
MCV	89			fL	79-97	01	F
MCH	30.1			pg	26.6-33.0	01	F
MCHC	34.0			g/dL	31.5-35.7	01	F
RDW	13.0			%	12.3-15.4	01	F
Platelets	252			x10E3/u L	150-379	01	F
Neutrophils	57			%	Not Estab.	01	F
Lymphs	33			%	Not Estab.	01	F
Monocytes	8			%	Not Estab.	01	F
Eos	2			%	Not Estab.	01	F
Basos	0			%	Not Estab.	01	F
Immature Cells	NP					01	X
Neutrophils (Absolute)	2.9			x10E3/u L	1.4-7.0	01	F
Lymphs (Absolute)	1.7			x10E3/u L	0.7-3.1	01	F
Monocytes(Absolute)	0.4			x10E3/u L	0.1-0.9	01	F
Eos (Absolute)	0.1			x10E3/u L	0.0-0.4	01	F
Baso (Absolute)	0.0			x10E3/u L	0.0-0.2	01	F
Immature Granulocytes	0			%	Not Estab.	01	F
Immature Grans (Abs)	0.0			x10E3/u L	0.0-0.1	01	F
NRBC	NP					01	X
Hematology Comments:	NP					01	X
<b>Comp. Metabolic Panel (14) [Final]</b>							
Glucose	82			mg/dL	65-99	01	F
BUN	17			mg/dL	6-20	01	F
Creatinine	1.25			mg/dL	0.76-1.27	01	F
eGFR If NonAfricn Am	73			mL/min/1 .73	>59	01	F
eGFR If Africn Am	84			mL/min/1 .73	>59	01	F
BUN/Creatinine Ratio	14				9-20	01	F
Sodium	140			mmol/L	134-144	01	F
Potassium	4.6			mmol/L	3.5-5.2	01	F
Chloride	102			mmol/L	96-106	01	F
Carbon Dioxide, Total	21			mmol/L	20-29	01	F
Calcium	9.5			mg/dL	8.7-10.2	01	F
Protein, Total	7.4			g/dL	6.0-8.5	01	F
Albumin	4.8			g/dL	3.5-5.5	01	F
Globulin, Total	2.6			g/dL	1.5-4.5	01	F
A/G Ratio	1.8				1.2-2.2	01	F
Bilirubin, Total	0.3			mg/dL	0.0-1.2	01	F

Comp. Metabolic Panel (14) [Final]							
Alkaline Phosphatase	75			IU/L	39-117	01	F
AST (SGOT)	22			IU/L	0-40	01	F
ALT (SGPT)	23			IU/L	0-44	01	F
Lipid Panel w/ Chol/HDL Ratio [Final]							
Cholesterol, Total		200	H	mg/dL	100-199	01	F
Triglycerides		164	H	mg/dL	0-149	01	F
HDL Cholesterol	44			mg/dL	>39	01	F
VLDL Cholesterol Cal	33			mg/dL	5-40	01	F
LDL Cholesterol Calc		123	H	mg/dL	0-99	01	F
Comment:	NP					01	X
T. Chol/HDL Ratio	4.5			ratio	0.0-5.0	01	F
Notes	T. Chol/HDL Ratio Men Women 1/2 Avg.Risk 3.4 3.3 Avg.Risk 5.0 4.4 2X Avg.Risk 9.6 7.1 3X Avg.Risk 23.4 11.0						
Testosterone,Free and Total [Final]							
Testosterone, Serum	478			ng/dL	264-916	01	F
Notes	Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017;102;1161-1173. PMID: 28324103.						
Free Testosterone(Direct)	10.8			pg/mL	8.7-25.1	02	F
Dihydrotestosterone [Final]							
Dihydrotestosterone	51			ng/dL		03	F
Notes	Reference Range: Adult Male: 30 - 85						
Thyroxine (T4) Free, Direct, S [Final]							
T4,Free(Direct)	1.38			ng/dL	0.82-1.77	01	F
DHEA-Sulfate [Final]							
DHEA-Sulfate	128.9			ug/dL	102.6-416.3	01	F
TSH [Final]							
TSH	0.996			uIU/mL	0.450-4.500	01	F
Luteinizing Hormone(LH), S [Final]							
LH	4.3			mIU/mL	1.7-8.6	01	F
Prolactin [Final]							
Prolactin	11.9			ng/mL	4.0-15.2	01	F
Prostate-Specific Ag, Serum [Final]							
Prostate Specific Ag, Serum	0.9			ng/mL	0.0-4.0	01	F
Notes	Roche ECLIA methodology.  According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absnce of malignant disease.						
IGF-1 [Final]							
Insulin-Like Growth Factor I	203			ng/mL	83-233	02	F

Estradiol, Sensitive	20.4			pg/mL	8.0-35.0	02	F
Notes	This test was developed and its performance characteristics determined by LabCorp. It has not been cleared by the Food and Drug Administration. Methodology: Liquid chromatography tandem mass spectrometry (LC/MS/MS)						
<b>Triiodothyronine (T3), Free [Final]</b>							
Triiodothyronine (T3), Free	3.2			pg/mL	2.0-4.4	01	F
<b>Sex Horm Binding Glob, Serum [Final]</b>							
Sex Horm Binding Glob, Serum	43.5			nmol/L	16.5-55.9	01	F
<b>Cardiovascular Report [Final]</b>							
Interpretation	Note					04	F
Notes	Supplemental report is available.						
PDF Image	.					04	F